 | Up a level |
Kashyap, Abhishek S; Schmittnaegel, Martina; Rigamonti, Nicolò; Pais-Ferreira, Daniela; Mueller, Philipp; Buchi, Melanie; Ooi, Chia-Huey; Kreuzaler, Matthias; Hirschmann, Petra; Guichard, Alan; Rieder, Natascha; Bill, Ruben; Herting, Frank; Kienast, Yvonne; Dirnhofer, Stefan; Klein, Christian; Hoves, Sabine; Ries, Carola H; Corse, Emily; De Palma, Michele; ... (2020). Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proceedings of the National Academy of Sciences of the United States of America - PNAS, 117(1), pp. 541-551. National Academy of Sciences NAS 10.1073/pnas.1902145116
Bill, Ruben; Schardt, Julian (2019). [Immunotherapies - Overview, mode of action and clinical implications]. Therapeutische Umschau, 76(4), pp. 187-194. Hogrefe 10.1024/0040-5930/a001083
Lüönd, Fabiana; Bill, Ruben; Vettiger, Andrea; Oller, Heide; Pelczar, Pawel; Christofori, Gerhard (2019). A Transgenic MMTV-Flippase Mouse Line for Molecular Engineering in Mammary Gland and Breast Cancer Mouse Models. Journal of mammary gland biology and neoplasia, 24(1), pp. 39-45. Springer 10.1007/s10911-018-9412-4
Tiede, Stefanie; Meyer-Schaller, Nathalie; Kalathur, Ravi Kiran Reddy; Ivanek, Robert; Fagiani, Ernesta; Schmassmann, Philip; Stillhard, Patrick; Häfliger, Simon; Kraut, Norbert; Schweifer, Norbert; Waizenegger, Irene C; Bill, Ruben; Christofori, Gerhard (2018). The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7(9), p. 73. Springer Nature 10.1038/s41389-018-0083-1
Bill, Ruben; Montani, Matteo; Blum, Benedikt; Dufour, Jean-François; Escher, Robert; Bühlmann, Michael (2018). Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology, 68(1), pp. 384-386. Wiley Interscience 10.1002/hep.29853
Wiedmer, Tabea; Blank, Annika; Pantasis, Sophia; Normand, Lea Elena Haaning; Bill, Ruben; Krebs, Philippe; Tschan, Mario; Marinoni, Ilaria; Perren, Aurel (2017). Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism. Molecular cancer therapeutics, 16(11), pp. 2502-2515. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-17-0136
